Company to Host Investor Webcast at 8:30 a.m. ET on
Friday, Sept. 18, 2020
DUBLIN, Sept. 8, 2020 /PRNewswire/ -- Alkermes
plc (Nasdaq: ALKS) today announced that it will present new
clinical data related to ALKS 4230, its investigational engineered
interleukin-2 (IL-2) variant immunotherapy, at the European Society
for Medical Oncology (ESMO) Virtual Congress, taking place
Sept. 18-21, 2020. Safety and
anti-tumor efficacy data from the ongoing phase 1/2 ARTISTRY-1
study, evaluating ALKS 4230 as monotherapy and in combination with
pembrolizumab in patients with refractory solid tumors, will be
shared in a mini oral presentation. The company will host an
accompanying webcast and conference call at 8:30 a.m. ET on
Friday, Sept. 18, 2020.
"The ESMO Virtual Congress serves as an important forum to share
the latest data on our immunotherapy candidate, ALKS 4230, with the
global oncology community," said Craig
Hopkinson, M.D., Chief Medical Officer and Executive Vice
President of Research & Development at Alkermes. "We look
forward to sharing new safety and efficacy data from our ARTISTRY-1
clinical trial, where we are evaluating ALKS 4230 as a monotherapy
and combination therapy to treat a variety of tumor types in
patients with tumors that are refractory to currently established
treatments."
A mini oral presentation (#1027) titled, "ALKS 4230 Monotherapy
and in Combination With Pembrolizumab in Patients With Refractory
Solid Tumors (ARTISTRY-1)," to be presented by Ulka N. Vaishampayan, M.D., Professor, Internal
Medicine, Division of Hematology/Oncology, University of Michigan, will be available on the
ESMO website at
https://www.esmo.org/meetings/esmo-virtual-congress-2020.
Conference Call and Webcast
Alkermes will host a
webcast presentation and conference call with accompanying slides
for analysts and investors on Friday, Sept.
18, 2020, at 8:30 a.m. ET
(1:30 p.m. BST) to discuss the latest
data from the ARTISTRY-1 clinical trial. The webcast will feature
the lead study investigator, Dr. Ulka N.
Vaishampayan, Professor of Internal Medicine, Division of
Hematology/Oncology, at the University of
Michigan, and members of Alkermes' management team. The
webcast player may be accessed on the Investors section of
Alkermes' website at www.alkermes.com. To participate in the
question and answer session, please also dial in to the conference
call, which may be accessed by dialing +1 877-407-2988 for U.S.
callers and +1 201-389-0923 for international callers. In addition,
a replay of the conference call may be accessed by visiting
Alkermes' website or by dialing +1 877-660-6853 for U.S. callers
and +1 201-612-7415 for international callers, using replay access
code 13708824. The conference call replay will be available from
11:30 a.m. ET (4:30 p.m. BST) on Friday,
Sept. 18, 2020 through Friday, Sept.
25, 2020.
About ALKS 4230
ALKS 4230 is an investigational,
novel, engineered fusion protein comprised of modified
interleukin-2 (IL-2) and the high affinity IL-2 alpha receptor
chain, designed to selectively expand tumor-killing immune cells
while avoiding the activation of immunosuppressive cells by
preferentially binding to the intermediate-affinity IL-2 receptor
complex. The selectivity of ALKS 4230 is designed to leverage the
proven anti-tumor effects of existing IL-2 therapy while mitigating
certain limitations.
About Alkermes
Alkermes plc is a fully integrated,
global biopharmaceutical company developing innovative medicines in
the fields of neuroscience and oncology. The company has a
portfolio of proprietary commercial products focused on addiction
and schizophrenia, and a pipeline of product candidates in
development for schizophrenia, bipolar I disorder,
neurodegenerative disorders and cancer. Headquartered in
Dublin, Ireland, Alkermes plc has
an R&D center in Waltham,
Massachusetts; a research and manufacturing facility in
Athlone, Ireland; and a
manufacturing facility in Wilmington,
Ohio. For more information, please visit Alkermes' website
at www.alkermes.com.
Alkermes Contacts:
For Investors: Sandy Coombs +1 781
609 6377
For Media: Sourojit Bhowmick, Ph.D. +1 781 609 6397
Logo
- https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg